Evidence map›Paper›PMID 29363049›Full record

ArticleInfection2018

Beta-lactams in continuous infusion for Gram-negative bacilli osteoarticular infections: an easy method for clinical use.

Alba Ribera, Laura Soldevila, Raul Rigo-Bonnin, Fe Tubau, Ariadna Padullés, Joan Gómez-Junyent, Javier Ariza, Oscar Murillo

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alba RiberaInfectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Laura SoldevilaInfectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Raul Rigo-BonninClinical Laboratory Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Fe TubauMicrobiology Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Ariadna PadullésPharmacy Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Joan Gómez-JunyentInfectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Javier ArizaInfectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain.
Oscar MurilloInfectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, Hospitalet de Llobregat, 08907, Barcelona, Spain. omurillo@bellvitgehospital.cat.
Institut d'Investigació Biomédica de Bellvitge · ESBellvitge University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Continuous infusion (CI) of beta-lactams could optimize their pharmacokinetic/pharmacodynamic indices, especially in difficult-to-treat infections. PURPOSE: To validate an easy-to-use method to guide beta-lactams dosage in CI (formula).

methodsA retrospective analysis was conducted of a prospectively collected cohort (n = 24 patients) with osteoarticular infections caused by Gram-negative bacilli (GNB) managed with beta-lactams in CI. Beta-lactams dose was calculated using a described formula (daily dose = 24 h × beta-lactam clearance × target "steady-state" concentration) to achieve concentrations above the MIC. We correlated the predicted concentration (C

resultsThe most frequent microorganism treated was P. aeruginosa (21 cases; 9 MDR). Beta-lactams in CI were ceftazidime (n = 14), aztreonam (7), and piperacillin/tazobactam (3), mainly used in combination (12 with colistin, 5 with ciprofloxacin) and administered without notable side effects. The plasma C

conclusionsThe formula may be useful in clinical practice for planning the initial dosage of beta-lactams in CI, while we await a systematic therapeutic drug monitoring. The use of beta-lactams in CI was safe.

Indexed as

AgedAnti-Bacterial Agentsbeta-LactamsBone Diseases, InfectiousFemaleGram-Negative BacteriaGram-Negative Bacterial InfectionsHumansInfusions, IntravenousMaleMicrobial Sensitivity TestsMiddle AgedRetrospective StudiesAnti-Bacterial Agentsbeta-LactamsAntibiotic plasma levelsBeta-lactamsBiofilm-related infectionsContinuous infusionGram-negative bacilliOsteoarticular infections

Identifiers

PMID29363049
OpenAlexW2784703807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.